NCT04825873View on ClinicalTrials.gov

A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China

CompletedOBSERVATIONAL
Enrollment

3,102

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

February 13, 2023

Study Completion Date

February 13, 2023

Conditions
Non-Small Cell Lung CancerSquamous Cell Carcinoma of Head and Neck
Trial Locations (2)

100050

Local Institution, Beijing

200120

Local Institution, Shanghai

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY